Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2006

View Archived Issues

BIM-28125: new ghrelin agonist improves glucocorticosteroid catabolic effects

FG-3019 has multiple effects in pancreatic cancer models

Clearance sought for study of oral interferon alpha in IPF

Ricerca BioSciences, new development partner for PhytoMedical's BDC-03

Athenagen and Zapaq to merge

TAK-491 for hypertension enters phase II

Portola studies oral Factor Xa inhibitor in knee replacement surgery patients

Antiarrhythmic efficacy and tolerability of the dual potassium/sodium channel blocker RSD-1235

Neose updates NE-180 progress

Xencor completes bridge financing

Alfacell forms collaboration for next-generation targeted therapies for cancer

Procter & Gamble and ARYx form alliance for GI drug ATI-7505

Novel antiinfective agents disclosed in recent patent literature

Curis and Genentech halt phase I basal cell carcinoma study

Phase I study of PhytoSel to lower side effects of chemotherapeutic drugs

EMEA clears Kamada's phase I plans for alpha-1 proteinase inhibitor

CB-7630 begins U.S. phase I study for advanced prostate cancer

Recent patents describe new therapeutic agents for diabetes

Eisai and Teva to end rasagiline collaboration agreement

Zhejiang University report on new antitumor agent targeted for cervical cancer

Banyu studies Gardasil in Japan

New possible treatments for metabolic disorders described in recent patents

Preclinical thrombolytic activity of HTU-PA shown in rat, hamster, rabbit and dog models

FDA approves Atripla, first once-daily single tablet regimen for HIV

Novel DHEA analogue shows antiarrhythmic potential without inducing QT prolongation

CJC-1295 normalizes body weight and length parameters in a mouse model of GH deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...